EI
ALXN

Elkhorn Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Elkhorn Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,180
Closed -$756K – 184
2016
Q4 		$756K Buy
+6,180
New +$756K 0.88% 70

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Elkhorn Investments's ALXN Position: Q1 2017 in Review

Elkhorn Investments sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 6,180 shares — an estimated $756K sold.

Elkhorn Investments first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $756K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

  • Elkhorn Investments reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Elkhorn Investments sold 6,180 Alexion Pharmaceuticals shares in Q1 2017, an estimated $756K.
  • Elkhorn Investments first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Elkhorn Investments's Alexion Pharmaceuticals position peaked at $756K in Q4 2016.
  • 561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on Elkhorn Investments's 13F filing for Q1 2017, filed 2 May 2017.